LAS VEGAS, Oct. 16 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN) is proud to announce that it has filed its SB-2 registration with the Securities and Exchange Commission. The company had announced previously its intention of becoming a fully reporting company under the 1934 Act, and today made it official. The company is next filing to be listed on the OTCBB following the effectiveness of the SB-2. "This is a monumental day for Mach One; we are now poised to move forward as fully reporting company with the next step -- the OTCBB," said Monte Tobin, CEO of Mach One. "Upon the effectiveness of the registration, we will make a public announcement for the benefit of our shareholders and future shareholders.
Mach One Corporation is currently trading on the Pink Sheets, under the symbol MNCN. Upon the effective date of the filing, the Company will attain Section 12 (g) reporting status with the SEC, under the Exchange Act of 1934, which will allow for broader market participation in the Company's shares by institutional investors. As a reporting company, Mach One Corporation will be required to file annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, and reports of unusual events on Form 8K. In addition, the Company will be required to solicit proxies for its annual meetings in accordance to Section 14 of the Securities Exchange Act of 1934 and other reporting requirements will apply to management shareholdings.
Investors can view the filing by accessing the SEC's website at http://www.sec.gov.
About Mach One Corporation
The company (http://www.machonecorp.com) specializes in Immune or Gamma Globulin replacement (IgG) for the equine and bovine markets. Through it's subsidiary company VDx, Inc., the company plans full scale manufacturing and distribution of Immunogam(TM), a colostrums replacement, supplement and prophylactic, in sterile powder form, that can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market along with an added ingredient for the elimination of Mastitis and Johnnes disease.
Cautionary Statement: This news release may include certain "Forward- looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.
|SOURCE Mach One Corporation|
Copyright©2007 PR Newswire.
All rights reserved